Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 20, 2026

Oral Hypoglycemic Agents: Biguanides and Glitazones
01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

594

[Biguanide]

Yasushi Tanaka1

  • 1Metabolism and Endocrinology, Department of Medicine, St. Marianna University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 10, 2012
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Last Updated: Jan 20, 2026

Oral Hypoglycemic Agents: Biguanides and Glitazones
01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

594

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

594
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
594

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Carbonated and Electrolyte-Added Water on Body Fluid Regulation and Ingestive Behavior During Ad Libitum Rehydration Following Mild Hypohydration.

Nutrients·2026
Same author

Exploring plasma cell-free RNA biomarkers for predicting immune checkpoint inhibitor efficacy in gastric cancer: a translational sub-study of the KSCC VOYAGER phase II trial.

International journal of clinical oncology·2026
Same author

Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomy.

BJC reports·2025
Same author

Polo-Like Kinase 1 Expression in Colorectal Cancer: Association With RAS Mutations.

Cancer science·2025
Same author

Differences in Tumor-Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma.

Cancer medicine·2025
Same author

The clinical significance of signal regulatory protein alpha expression in the immune environment of gastric cancer.

International journal of clinical oncology·2024